Search research articles
Contact Us
Filters
Showing results (231-240 of 246) with videos related to
Page
of 25
Sort By:
The New England Journal of Medicine
|
December 10, 2021
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
Frederick L Locke, David B Miklos, Caron A Jacobson, et al.
Blood
|
December 1, 2020
Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy
Anthony R Mato, Nilanjan Ghosh, Stephen J Schuster, et al.
American Journal of Hematology
|
August 23, 2018
Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial
Anthony R Mato, Lindsey E Roeker, John N Allan, et al.
JCO Oncology Practice
|
March 20, 2025
Erratum: Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid Leukemia
John M Pagel, Megan Othus, Guillermo Garcia-Manero, et al.
JCO Oncology Practice
|
February 13, 2020
Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid Leukemia
John M Pagel, Megan Othus, Guillermo Garcia-Manero, et al.
Blood Advances
|
September 21, 2021
Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies
Matthew S Davids, Owen A O'Connor, Wojciech Jurczak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 19, 2024
Randomized Phase III SIERRA Trial of <sup>131</sup>I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML
Boglarka Gyurkocza, Rajneesh Nath, Stuart Seropian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 21, 2019
Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice
Lindsey E Roeker, Christopher P Fox, Toby A Eyre, et al.
Blood Advances
|
May 19, 2019
A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL
Anthony R Mato, Lindsey E Roeker, Toby A Eyre, et al.
Lancet (London, England)
|
March 7, 2021
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
Anthony R Mato, Nirav N Shah, Wojciech Jurczak, et al.
Page
of 25
Search research articles
Search
Showing results (231-240 of 246) with videos related to
Sort By:
Page
of 25
The New England Journal of Medicine
|
December 10, 2021
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
Frederick L Locke, David B Miklos, Caron A Jacobson, et al.
Blood
|
December 1, 2020
Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy
Anthony R Mato, Nilanjan Ghosh, Stephen J Schuster, et al.
American Journal of Hematology
|
August 23, 2018
Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial
Anthony R Mato, Lindsey E Roeker, John N Allan, et al.
JCO Oncology Practice
|
March 20, 2025
Erratum: Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid Leukemia
John M Pagel, Megan Othus, Guillermo Garcia-Manero, et al.
JCO Oncology Practice
|
February 13, 2020
Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid Leukemia
John M Pagel, Megan Othus, Guillermo Garcia-Manero, et al.
Blood Advances
|
September 21, 2021
Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies
Matthew S Davids, Owen A O'Connor, Wojciech Jurczak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 19, 2024
Randomized Phase III SIERRA Trial of <sup>131</sup>I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML
Boglarka Gyurkocza, Rajneesh Nath, Stuart Seropian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 21, 2019
Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice
Lindsey E Roeker, Christopher P Fox, Toby A Eyre, et al.
Blood Advances
|
May 19, 2019
A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL
Anthony R Mato, Lindsey E Roeker, Toby A Eyre, et al.
Lancet (London, England)
|
March 7, 2021
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
Anthony R Mato, Nirav N Shah, Wojciech Jurczak, et al.
Page
of 25